Prescription of antiviral therapy after herpes zoster in general practice: Who receives therapy?

British Journal of General Practice

Volumn 62, Issue 605, 2012, Pages

  Forbes, Harriet J ^a   Thomas, Sara L ^a   Smeeth, Liam ^a   Langan, Sinéad M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antivirals; Database; Epidemiology; General practice; GPRD; Herpes zoster; Shingles; United Kingdom

Indexed keywords

ACICLOVIR; FAMCICLOVIR; VALACICLOVIR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ELECTRONIC MEDICAL RECORD; FEMALE; GENERAL PRACTICE; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RISK FACTOR; SOCIAL STATUS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; ARTHRITIS, RHEUMATOID; ENGLAND; FAMILY PRACTICE; FEMALE; HERPES ZOSTER; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RESIDENCE CHARACTERISTICS; SEX DISTRIBUTION; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84870716275     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp12X659277     Document Type: Article

References (18)

1. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347(5): 340-346.
2. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004; 4(1): 26-33. (Pubitemid 38057055)
3. Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009; 137(1): 38-47.
4. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1: S1-S26. (Pubitemid 44956795)
5. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995; 123(2): 89-96.
6. Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22(2): 341-347. (Pubitemid 26056166)
7. Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009; (2): CD006866.
8. Clinical Knowledge Summaries. Shingles - management. When should I prescribe an antiviral drug? CKS, 2012. http://www.cks.nhs.uk/shingles/ management/scenario-shingles/when-to-prescribe-an-antiviral-drug/ basis-for-recommendation#-338090 (accessed 31 Oct 2012).
9. Lewis J, Bilker W, Weinstein R, Strom B. The relationship between time since registration and measured incidence rates in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2005; 14(7): 443-451. (Pubitemid 40990739)
10. Noble M, McLennan D, Wilkinson K, et al. The English Indices of Deprivation 2007. London: Communities and Local Government, 2008.
11. Decroix J, Partsch H, Gonzalez R, et al. Factors influencing pain outcome in herpes zoster: an observational study with valaciclovir. Valaciclovir International Zoster Assessment Group (VIZA). J Eur Acad Dermatol Venereol 2000; 14(1): 23-33. (Pubitemid 32899317)
12. Kurokawa I, Kumano K, Murakawa K. Clinical correlates of prolonged pain in Japanese patients with acute herpes zoster. J Int Med Res 2002; 30(1): 56-65. (Pubitemid 34618723)
13. Scott FT, Johnson RW, Leedham-Green M, et al. The burden of herpes zoster: a prospective population based study. Vaccine 2006; 24(9): 1308-1314. (Pubitemid 43222038)
14. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360(9334): 678-682. (Pubitemid 35232336)
15. Gialloreti LE, Merito M, Pezzotti P, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis 2010; 10: 230.
16. Stein AN, Britt H, Harrison C, et al. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 2009; 27(4): 520-529.
17. Insinga RP, Itzler RF, Pellissier JM. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 2007; 25(2): 155-169. (Pubitemid 46175551)
18. Opstelten W, van Essen GA, Moons KG, et al. Do herpes zoster patients receive antivirals? A Dutch National Survey in General Practice. Fam Pract 2005; 22(5): 523-528. (Pubitemid 41418771)